key: cord-0995857-n4gskih2
authors: Riva, Giovanni; Nasillo, Vincenzo; Luppi, Mario; Tagliafico, Enrico; Trenti, Tommaso
title: Linking COVID-19, monocyte activation and sepsis: MDW, a novel biomarker from cytometry
date: 2021-12-15
journal: EBioMedicine
DOI: 10.1016/j.ebiom.2021.103754
sha: 3c4abdfcb6e128a28e12d5fcb1ca3c6b3bf3c5f8
doc_id: 995857
cord_uid: n4gskih2

nan

Linking COVID-19, monocyte activation and sepsis: MDW, a novel biomarker from cytometry Circulating monocytes, recruited from the bone marrow to injured organs upon infection or tissue damage, stay at the complex intersection of immune defence, systemic inflammation and tissue repair. Indeed, monocytes and monocyte-derived macrophages are key regulators of both innate and adaptive cellular immunity, as well as humoral inflammation, complement cascade and plasma coagulation. Upon activation, these cells undergo structural and functional modifications, enabling a broad set of immunomodulatory activities, mainly exerted by either proinflammatory or inhibitory cytokines, chemokines, and other inflammatory mediators, as well as by cell-to-cell interactions and phagocytosis. As supported by several lines of evidence, monocyte/macrophage dysregulation may represent the cornerstone of the systemic hyper-inflammatory response (cytokine storm), coagulopathy and lung damage (respiratory failure), characterizing the severe form of COVID-19. 1 Monocyte Distribution Width (MDW), an emerging cytometric parameter, automatically calculated within complete blood count by novel haematology analyzers, is linked to volume modifications occurring in the whole monocyte population upon massive immune activation. Consistent with this, MDW was originally described as an 'early sepsis indicator' in the Emergency Department (ED) and Intensive Care Unit (ICU), and, recently, different reports have shown some promising MDW applications also in COVID-19 patients. Together, these works well evidenced that MDW is sig-nificantly higher in COVID-19 than in non-COVID-19 cases, thus suggesting that upfront MDW measurement, while awaiting SARS-CoV-2 molecular results, could allow a prompt differential diagnosis in the emergency setting. 2 Intriguingly, by providing a conceptual link between the diagnosis of sepsis and COVID-19, MDW findings can further support the notion that severe COVID-19 may constitute a (new) kind of viral sepsis. 3 Moreover, recent pilot studies have disclosed that MDW testing may also be exploited for prognostic monitoring in hospitalized COVID-19 patients, either alone, 4 or in combination with Neutrophil-to-Lymphocyte Ratio (NLR). 5 In this view, by considering both the biological rationale and clinical data reported so far, MDW can represent a useful haematological (cell-based) parameter, related to monocyte activation typically occurring in lifethreatening (dis)inflammatory conditions, such as sepsis and COVID-19. In particular, MDW could be relevant as a prognostic factor in the management of COVID-19 patients ( Figure 1 ). Further investigations are warranted to define optimal MDW thresholds, potentially improving the continuous risk assessment in COVID-19 patients, at different clinical stages. In perspective, additional studies involving large cohorts are needed to shed more light on the prognostic role of MDW in this context, possibly in combination with other cellular and humoral biomarkers, aiming to identify predictive tools for helping the therapeutic decisionmaking in patients with SARS-CoV-2 infection. 

Monocyte activation in systemic COVID-19 infection: assay and rationale. EBioMedicine 2020

Pooled analysis of monocyte distribution width in subjects with SARS-CoV-2 infection

COVID-19: more than a cytokine storm

Monocyte distribution width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients

Monocyte distribution width adds prognostic value in detection of COVID-19 respiratory failure [published online ahead of print

The authors declare no funding sources related to this work.